Self-Assembling Peptide P11-4

What it is

P11-4 is a rationally designed 11-amino-acid peptide with the sequence QQRFEWEFEQQ. It is not a protein isolated from a natural source but a molecule engineered from scratch for a single purpose: to spontaneously assemble into a three-dimensional fibrillar mesh under the right conditions. Under INCI nomenclature it is listed as Oligopeptide-104.

The fundamental difference between this peptide and classical remineralizers is that it carries no pre-formed mineral of its own. Nano-hydroxyapatite and calcium phosphates deliver ready-made building blocks to the enamel surface. P11-4 works differently — it builds a template matrix on which apatite crystals grow anew from ions already dissolved in saliva.

Commercially the peptide is known through CUROLOX technology and the Curodont Repair product — a professional treatment for early, not-yet-cavitated caries lesions (ICDAS 1–2). Its working concentration in Curodont is around 1000 ppm, and it is applied in the dental chair rather than at home.

How it works

The key mechanism is triggered self-assembly. In a neutral environment the peptide solution stays fluid and free-flowing, which lets it penetrate deep into the porous body of an early demineralization lesion. But as soon as the peptide reaches an acidic environment with a specific ionic strength — exactly the conditions inside a caries lesion — the molecules change conformation and spontaneously cross-link into a three-dimensional fibrillar scaffold (a biomimetic matrix).

This scaffold acts as a nucleation template. Its surface is charged so that it attracts calcium and phosphate ions from saliva and holds them in the correct geometry. On this matrix, de novo nucleation of hydroxyapatite crystals begins — meaning new mineral phase grows not just on the surface but throughout the depth of the lesion.

This is why the approach is called guided enamel regeneration or regenerative remineralization. Unlike surface mineral deposition, the peptide rebuilds structure from inside the lesion body, replicating the logic of natural mineralization. Along the way the mesh occupies open dentinal tubules and porosities, which produces a sensitivity-reduction effect.

Efficacy

The evidence base for P11-4 is unusually strong for a "new" active because it was developed in a clinical setting. The first in-human study — the RCT by Brunton et al. (2013, PMID 23579164) — was primarily about safety, but it already showed regression of early lesions versus a fluoride control with no adverse events.

Later work added efficacy numbers. Alkilzy et al. (2018, J Dent Res, PMID 29355434) showed in an RCT that combining P11-4 with fluoride produced a statistically significantly greater reduction in lesion size and a greater mineral gain than fluoride alone. This is an important nuance: the peptide is not pitted against fluoride but works synergistically with it — the scaffold defines the geometry, the fluoride accelerates mineralization.

A separate line of data concerns reduced hypersensitivity. Work by Schlee et al. (2018) showed a clinically meaningful reduction in dentine sensitivity through tubule occlusion by the mineralized scaffold. Reviews, in particular Sedlakova Kondelova et al. (2020), conclude that for initial caries lesions P11-4 is one of the most evidence-based biomimetic approaches, while honestly noting the need for larger and longer studies.

Safety

The safety profile of P11-4 is favorable. It is a short synthetic peptide that, after self-assembly and mineralization, becomes part of the apatite structure; no meaningful systemic absorption is expected. In the first clinical safety study (Brunton 2013) no adverse reactions were recorded.

The one substantive caveat concerns the format of use, not the molecule itself. This is a professional product: it is applied by a dentist after diagnosing early lesions, under controlled conditions. Self-directed home use of the peptide at Curodont concentration is not currently intended, and this is not a safety shortcoming but a feature of the technology and its maturity stage.

For a mass-market dentifrice, open questions remain around cost, the stability of the peptide inside a toothpaste formula, and raw-material availability. That is why we treat P11-4 as a directional benchmark rather than an ingredient ready to drop into a tube tomorrow.

Role in the QDRO formula

P11-4 is a flagship benchmark among emerging biomimetics and fits perfectly into the philosophy of the v.pro "Second Enamel" line. The core idea — not just to halt demineralization but to restart the growth of the mineral phase along a natural blueprint — is exactly what the brand builds into its regenerative positioning.

At the same time we keep an honest distance. As of today P11-4 is a professional treatment, not a proven mass-market active for a home toothpaste. So in our own formulas the working regenerative load is carried by nano-hydroxyapatite — it delivers ready-made apatite, has a clear profile, and is available at the required quality. P11-4 we use as a scientific vector: it shows where remineralization is heading and what result should count as "complete".

The practical takeaway for the reader: if you have an early, not-yet-cavitated lesion or marked sensitivity, professional application of P11-4 is worth discussing with your dentist. Day-to-day support comes from a well-built nano-hydroxyapatite toothpaste — and it is on this pairing of "professional peptide plus home apatite" that our view of enamel regeneration rests.